-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Htg Molecular Diagnostics, Inc quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from 2014 to 2022.
- Htg Molecular Diagnostics, Inc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending March 31, 2023 was -$5.05M, a 22.2% increase year-over-year.
- Htg Molecular Diagnostics, Inc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending March 31, 2023 was -$20.1M, a 7.27% decline year-over-year.
- Htg Molecular Diagnostics, Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was -$21.6M, a 26.1% decline from 2021.
- Htg Molecular Diagnostics, Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was -$17.1M, a 17.9% increase from 2020.
- Htg Molecular Diagnostics, Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2020 was -$20.9M, a 8.09% decline from 2019.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Growth (%)